Compare IDEXX Laboratories, Inc. (IDXX) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Verisign, Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $560 (market cap $44.48B), while Verisign, Inc. trades at $276.51 (market cap $25.26B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Verisign, Inc. pays a 1.17% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | VRSN | |
|---|---|---|
Market Cap | $44.48B | $25.26B |
Sector | Health | Technology |
52-Week High | $766.68 | $310.00 |
52-Week Low | $520.87 | $211.49 |
Enterprise Value | $45.38B | $26.50B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
VeriSign (VRSN) trades at $277.60, down slightly by 0.02% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q1 2026 results with EPS of $2.34 beating estimates, driven by 6.6% revenue growth. Analyst consensus is a Buy with a $325.25 price target, reflecting confidence in its domain registry monopoly and robust margins.
Outlook remains positive due to predictable revenue streams from .com and .net domains, though risks include AI disruption and contract renewals. Valuation multiples like P/E of 30.68 appear elevated, requiring sustained growth to justify. Investors should weigh high margins against debt levels and competitive threats for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
